z-logo
Premium
Self‐Assembled Supramolecular Hetero‐Bimetallacycles for Anticancer Potency by Intracellular Release
Author(s) -
Mishra Anurag,
Chang Lee Seung,
Kaushik Neha,
Cook Timothy R.,
Choi Eun Ha,
Kumar Kaushik Nagendra,
Stang Peter J.,
Chi KiWhan
Publication year - 2014
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201403372
Subject(s) - chemistry , cytotoxicity , trifluoromethanesulfonate , stereochemistry , annexin , supramolecular chemistry , pyridine , apoptosis , cancer cell , cisplatin , medicinal chemistry , crystallography , crystal structure , biochemistry , in vitro , cancer , catalysis , medicine , surgery , chemotherapy
Abstract Two new tetracationic hetero‐bimetallacycles, compounds 4 and 5 , have been constructed from an N , N ′‐bis(4‐(pyridin‐4‐ylethynyl)phenyl)pyridine‐2,6‐dicarboxamide ligand ( 1 ), and cis ‐blocked complexes [M(dppf)(OTf) 2 ] (dppf=1,1′‐bis(diphenylphosphino)ferrocene; OTf=trifluoromethanesulfonate; M=Pd ( 2 ), Pt ( 3 )) in CH 3 NO 2 /CH 2 Cl 2 (1:1) solvent. Both complexes were isolated with adequate yields as triflate salts and were then characterized using 1 H, 13 C, and 31 P NMR spectroscopy, elemental analysis, UV/Vis spectroscopy, and high‐resolution electrospray mass spectrometry (HR‐ESMS). The molecular structure of 4 was determined by molecular mechanics force‐field calculations. The cytotoxic effect of both new complexes were analyzed against T98G (brain tumor), KB (head and neck cancer), SNU‐80 (thyroid cancer), and HEK‐293 non‐malignant cell lines. The cytotoxicity of complexes 4 and 5 were found to be considerably more effective against cancer cells than reference drug cisplatin. Annexin‐V/PI staining, caspase‐3/7 activity, and the reduction in mitochondrial membrane potential justify a significant level of apoptosis in complex‐treated cells.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here